JP2014530240A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530240A5
JP2014530240A5 JP2014535916A JP2014535916A JP2014530240A5 JP 2014530240 A5 JP2014530240 A5 JP 2014530240A5 JP 2014535916 A JP2014535916 A JP 2014535916A JP 2014535916 A JP2014535916 A JP 2014535916A JP 2014530240 A5 JP2014530240 A5 JP 2014530240A5
Authority
JP
Japan
Prior art keywords
alkyl
group
alkylene
conh
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530240A (ja
JP6033318B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059932 external-priority patent/WO2013056034A1/en
Publication of JP2014530240A publication Critical patent/JP2014530240A/ja
Publication of JP2014530240A5 publication Critical patent/JP2014530240A5/ja
Application granted granted Critical
Publication of JP6033318B2 publication Critical patent/JP6033318B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535916A 2011-10-14 2012-10-12 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物 Expired - Fee Related JP6033318B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547301P 2011-10-14 2011-10-14
US61/547,301 2011-10-14
PCT/US2012/059932 WO2013056034A1 (en) 2011-10-14 2012-10-12 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Publications (3)

Publication Number Publication Date
JP2014530240A JP2014530240A (ja) 2014-11-17
JP2014530240A5 true JP2014530240A5 (enExample) 2015-12-03
JP6033318B2 JP6033318B2 (ja) 2016-11-30

Family

ID=47116434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535916A Expired - Fee Related JP6033318B2 (ja) 2011-10-14 2012-10-12 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物

Country Status (7)

Country Link
US (1) US9079929B2 (enExample)
EP (1) EP2766347B1 (enExample)
JP (1) JP6033318B2 (enExample)
CN (1) CN103987696B (enExample)
ES (1) ES2579832T3 (enExample)
IN (1) IN2014CN02805A (enExample)
WO (1) WO2013056034A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2876105A4 (en) 2012-07-19 2016-01-13 Sumitomo Dainippon Pharma Co Ltd 1- (CYCLOALKYL-CARBONYL) PROLIN DERIVATIVE
LT2882734T (lt) 2012-08-03 2016-12-12 Bristol-Myers Squibb Company Dihidropiridonai, kaip xia faktoriaus slopikliai
PT2880026T (pt) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2906551B1 (en) 2012-10-12 2018-02-28 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059214A1 (en) * 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
BR112015021449B1 (pt) * 2013-03-05 2020-05-05 Bayer Cropscience Ag uso de acilsulfonamidas para melhorar a produção da planta
EP2978751B1 (en) * 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
EP3054944B1 (en) * 2013-10-07 2019-12-04 Merck Sharp & Dohme Corp. Factor xia inhibitors
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
NO2760821T3 (enExample) 2014-01-31 2018-03-10
WO2015123093A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3104702B1 (en) 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TN2016000567A1 (en) * 2014-07-01 2018-04-04 Takeda Pharmaceuticals Co Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2722425T3 (es) * 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6742348B2 (ja) 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのジアミド大員環
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
JP6629958B2 (ja) 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アルキルまたはシクロアルキルP2’基を担持する大員環の第XIa因子阻害剤
CN108137549B (zh) * 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
MX387515B (es) 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
EP3371162B1 (en) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2017123518A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
JP7010834B2 (ja) * 2016-03-17 2022-02-10 チェックメイト セラピューティクス インコーポレイテッド ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CA3031592A1 (en) 2016-08-31 2018-03-08 Jiangsu Hengrui Medicine Co., Ltd. Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
CN109721539B (zh) * 2017-10-27 2021-07-09 天津药物研究院有限公司 吡唑酰胺类衍生物及其制备方法和用途
CN109867660A (zh) * 2017-12-01 2019-06-11 四川科伦博泰生物医药股份有限公司 含季铵离子的四氢异喹啉酰胺化合物及其药物用途
WO2019184744A1 (zh) * 2018-03-28 2019-10-03 四川科伦博泰生物医药股份有限公司 四氢异喹啉类衍生物及其制备方法和用途
WO2020243049A1 (en) * 2019-05-30 2020-12-03 Merck Sharp & Dohme Corp. Factor xi activation inhibitors
EP4125892A4 (en) * 2020-04-01 2024-04-03 Merck Sharp & Dohme LLC Factor xi activation inhibitors
EP4149917B1 (en) * 2020-05-12 2025-07-30 Merck Sharp & Dohme LLC Factor xi activation inhibitors
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU717298B2 (en) 1996-04-03 2000-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
CA2324226C (en) 1998-03-19 2012-06-05 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
KR20010101355A (ko) 1999-01-02 2001-11-14 로버트 흐라이탁, 미쉘 베스트 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 xa 활성 억제)
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
IL145771A0 (en) 1999-04-09 2002-07-25 Basf Ag Low-molecular inhibitors of complement proteases
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
EP1427415B1 (en) 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003041641A2 (en) * 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Xia因子阻害剤としての置換ビアリール化合物
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
BRPI0612621B8 (pt) 2005-06-17 2017-03-21 Basf Ag processo para produzir compostos químicos, e, composto
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
EP1981854B1 (en) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
BRPI0716715B1 (pt) 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
EP2152664B1 (en) * 2007-06-13 2014-09-03 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
EP2729150B1 (en) 2011-07-08 2016-09-14 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
DK2794597T3 (en) 2011-12-21 2018-01-15 Ono Pharmaceutical Co PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 3位置換プロリン誘導体
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
EP2876105A4 (en) 2012-07-19 2016-01-13 Sumitomo Dainippon Pharma Co Ltd 1- (CYCLOALKYL-CARBONYL) PROLIN DERIVATIVE
LT2882734T (lt) 2012-08-03 2016-12-12 Bristol-Myers Squibb Company Dihidropiridonai, kaip xia faktoriaus slopikliai
PT2880026T (pt) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia

Similar Documents

Publication Publication Date Title
JP2014532070A5 (enExample)
JP2014521700A5 (enExample)
JP2014521701A5 (enExample)
HRP20170784T1 (hr) Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora
JP2011520967A5 (enExample)
JP2017504642A5 (enExample)
JP2024513881A5 (enExample)
JP2014528479A5 (enExample)
JP2004509114A5 (enExample)
JP2017525744A5 (enExample)
RU2014152276A (ru) Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний
IL161337A (en) N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
JP2017504640A5 (enExample)
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
JP2009536218A5 (enExample)
IL298983B2 (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
RU2005118982A (ru) Производные замещенного дигидропираноиндол-3, 4-диона как ингибиторы ингибитора-1 активатора плазминогена (pai)
JP2018520195A5 (enExample)
JP2017504641A5 (enExample)
JP2016519096A5 (enExample)
JP2017513932A5 (enExample)
JP2004509113A5 (enExample)
HRP20171950T1 (hr) Pirimidinoni kao inhibitori faktora xia
HRP20180465T1 (hr) Kristalni oblici inhibitora faktora xia
JP2023544476A5 (enExample)